Skip to main content
Premium Trial:

Request an Annual Quote

Aclara Reports Flat Revenues, Widened Losses

SAN FRANCISCO, Nov. 7 - Aclara BioSciences today reported approximately flat revenue for the third quarter of 2002.


The company said its total revenue was $505,000 in the third quarter which ended September 30, compared to $507,000 in the same quarter of 2001.


Aclara reported a net loss based on generally accepted accounting principles of $11.2 million, or $.31 per share, in the third quarter 2002 compared to a net loss of $9.1 million, or $.26 per share, in the year-ago period. The company said the increased loss in part reflects higher costs associated with a focus on the commercialization of its eTag assay systems, a move the company said deemphasizes microfluidic product development and lead to the firing of approximately 50 employees.


R&D spending decreased to $5.4 million compared to $5.8 million in the same period a year ago.


Aclara also reported $85.2 million in cash, cash equivalents, and short-term investments at the end of September 2002.


Click here for more information.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.